Related Experiment Video
Updated: Jun 6, 2025
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Evaluation of Subclinical Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Hematopoietic Stem Cell
Audrone Vaitiekiene1, Migle Kulboke2,3, Monika Bieseviciene1
1Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Insights
Cancer therapy-related cardiac dysfunction (CTRCD) affects 27.3% of patients 12 months post-hematopoietic stem cell transplantation (HSCT). Prior anthracycline use and BEAM conditioning increase CTRCD risk.
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- Hematopoietic stem cell transplantation (HSCT) is a vital cancer treatment.
- Increasing HSCT procedures correlate with rising cancer therapy-related cardiac dysfunction (CTRCD).
Purpose of the Study:
- Determine the prevalence of subclinical CTRCD 12 months after HSCT.
- Identify clinical factors associated with CTRCD development post-HSCT.
Main Methods:
- Echocardiography assessment of 55 HSCT patients (autologous/allogeneic) before and 12 months post-transplant.
- Analysis of clinical data, including prior anthracycline exposure and conditioning regimens.
Main Results:
- Asymptomatic CTRCD detected in 27.3% (15/55) of patients at 12 months post-HSCT.
- Prior anthracycline use was linked to higher CTRCD rates (60% vs. 22.5%).
- BEAM conditioning regimen was associated with increased CTRCD incidence (33.3% vs. 5%).
Conclusions:
- Subclinical CTRCD is prevalent (27.3%) 12 months after HSCT.
- Anthracycline exposure and BEAM conditioning are significant risk factors for CTRCD development.
Abstract:
Background: Hematopoietic stem cell transplantation (HSCT) is a potentially curative procedure that is used in various hematological malignancies. However, among an increasing number of HSCT, the amount of cancer therapy-related cardiac dysfunction (CTRCD) is increasing as well. This study aimed to determine the prevalence of subclinical CTRCD in HSCT patients 12 months after HSCT and to assess the impact of clinical factors on the development of CTRCD. Material and Methods: We included 55 patients who underwent autologous or allogeneic HSCT. The patients were assessed using an echocardiography method before and 12 months after a HSCT procedure. Results: Our study revealed that during the 12-month follow-up period, asymptomatic CTRCD was observed in 15 patients (27.3%), 6 experienced moderate CTRCD, and 9 experienced mild CTRCD. Patients with previous use of anthracyclines tended to have CTRCD more often: nine patients (60%) in the CTRCD group and nine patients (22.5%) in non-CTRCD group. Patients who received the BEAM regimen for conditioning also experienced CTRCD more often: five patients (33.3%) in CTRCD group vs. two patients (5%) in the non-CTRCD group. Conclusions: Our study showed that asymptomatic CTRCD was found in 27.3% of the patients 12 months after HSCT. The BEAM chemotherapy conditioning protocol following prior anthracycline use were identified as factors contributing to the development of CTRCD.
Related Concept Videos
01:17Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
01:20Imaging Studies for Cardiovascular System II:Types of Echocardiography
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies